Polo's extensive regulatory leadership experience is a welcome addition to Shionogi at this pivotal time for the company in the U.S.," said Nate McCutcheon, President and Chief Executive Officer, Shionogi Inc. "As a leader in infectious disease, our robust clinical development program includes a late-stage investigational oral antiviral for COVID-19 and early-stage antibiotic programs through our acquisition of Qpex. We are also progressing additional key programs in other therapeutic areas with an investigational treatment for Fragile X syndrome in Phase 2b/3 studies and studies underway for acute ischemic stroke, obesity and oncology." Dr. Polo's diverse expertise includes overseeing clinical development operations, pharmacovigilance programs and regulatory strategies. He joins Shionogi Inc. from Johnson & Johnson, where he served as the Vice President, Head of Infectious Diseases, Vaccines & Global Public Health Regulatory Affairs.